Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Ginkgo Bioworks Holdings Inc (DNA) vs MetLife Inc. Common Stock (MET) Price & Performance

Ginkgo Bioworks Holdings IncTrade
MetLife Inc. Common StockTrade

Price performance (Past 24H)

Key statistics

Ginkgo Bioworks Holdings Inc vs MetLife Inc. Common Stock — how do they compare? Ginkgo Bioworks Holdings Inc trades at $13.08 (market cap $763.64M), while MetLife Inc. Common Stock trades at $98.02 (market cap $62.58B). The key difference: MetLife Inc. Common Stock is far larger — about 81.9× Ginkgo Bioworks Holdings Inc's market cap, and MetLife Inc. Common Stock pays a 2.41% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and MetLife Inc. Common Stock for 0 Days on average.

DNAMET
Market Cap
$763.64M$62.58B
Volume
3,204,1773,009,466
Sector
HealthFinancials
52-Week High
$15.83$99.95
52-Week Low
$5.48$67.70
Typical Hold Time
7 Days0 Days
Enterprise Value
$865.59M$83.50B
Dividend Yield
—2.41%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks (DNA) trades at $12.84, up 11.94% in the last session. The stock shows a bullish technical signal with strong moving average support, though oscillators are neutral. Fundamentally, the company reported a net loss of $312.76 million in 2025 on $170.16 million revenue, with a negative net margin of 219.6%. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting strategic growth initiatives despite financial challenges.

Outlook remains speculative with high risk. The buy/hold/sell analyst split is nearly even, reflecting uncertainty. Significant cash burn and persistent losses pose substantial risks, but partnerships and government contracts offer potential catalysts. Investors should weigh the company's long-term biotechnology prospects against its current lack of profitability and negative cash flow.

MetLife Inc. Common Stock

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

DNA
53% Buy47% Sell
Avg holding period · 7 Days
MET
100% Buy0% Sell
Avg holding period · 0 Days

Top news

Latest headlines on both assets

About Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.

Read more on DNA →

About MetLife Inc. Common Stock

MetLife provides insurance, annuities, employee benefits, and asset management services. Its products serve individuals, employers, and institutions.

Read more on MET →